BioSpace News Archive

Nevro Corp. (NYSE: NVRO) today announced that two abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Back Pain (NSBP) were accepted for podium presentations at the 2023 North American Neuromodulation Society Annual Meeting (NANS 2023), and will be presented during the late-breaking plenary sessions on January 13-14, 2023 in Las Vegas, NV.

Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.

MoonLake Immunotherapeutics AG (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that the first subject has been screened in the United States, in a Phase 2 clinical study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (PsA).

scPharmaceuticals Inc. announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco.

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced a $32M equity investment, from a large medical device innovator.

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced the selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program.

BioSig Technologies, Inc. announced that its PURE EP™ System was featured in an abstract presentation during the 15th Asia Pacific Heart Rhythm Society Scientific Session in Singapore.

Gradalis, a privately-held, late-stage stage biotechnology company developing immunotherapies for ovarian and other cancers, announced the appointment of Eric Hall, CFA, as Chief Financial Officer, effective January 1, 2023.

Immix Biopharma, Inc. announced that it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cutoff with a median of 6 prior lines of therapy.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology.